Oscar Health is a New York-based, technology-driven health insurer offering individual and family (primarily ACA marketplace), small-group, and Medicare Advantage plans, alongside its licensed "+Oscar" technology platform. The company is led by CEO Mark Bertolini, formerly of Aetna.
The $37 central target is calculated from nine current, individually verified analyst price targets rather than copied from any single headline consensus. The targets reviewed include Barclays ($49), Piper Sandler ($45), Raymond James ($42), UBS ($38), Stephens & Co. ($34), Baird ($33), Jefferies ($31), Bank of America Securities ($30), and Wells Fargo ($27), spanning roughly August through November 2026. Their arithmetic mean is approximately $36.60, which rounds to a clean $37.
The dispersion is striking. Barclays, Piper Sandler, and Raymond James carry bullish stances well above the mean, while Bank of America Securities remains Underperform and Wells Fargo sits at the low end. Most firms have neutral ratings, a sign that analysts see the growth story as real but largely priced in. Notably, several firms — Barclays, UBS, and Jefferies — upgraded OSCR from bearish stances during 2026, and targets have generally been revised upward as results improved.
With shares near $32.14, moving to $37 requires about a 15% gain — a substantial but not extraordinary move for a stock that has already climbed more than 120% year to date and trades well above its 52-week low of $10.69. The 52-week high sits near $38.50, meaning the central target sits just below the stock's own recent peak.
The path would likely depend on continued execution: sustained premium revenue growth, stable or improving medical cost ratios, and delivery on the raised full-year 2026 operating-earnings guidance of $850 million to $950 million. Revenue is projected to reach roughly $18.99 billion in 2026, up more than 60% from 2025, with EPS (earnings per share) forecast around $2.17 versus a loss the prior year. A forward P/E (price-to-earnings ratio) near 15 leaves some room for multiple expansion if earnings keep compounding, but also limits downside cushion if growth decelerates.
The most compelling support is the company's dramatic swing to profitability. Third-quarter 2026 revenue rose more than 70% year over year, and management lifted full-year operating-earnings guidance — evidence that scale is translating into operating leverage. Expansion to roughly 713 counties across 21 states broadens the growth runway, while the +Oscar licensing business offers a non-premium revenue stream. A steady cadence of analyst upgrades through 2026 — Barclays to Overweight and UBS from Sell to Neutral among them — reflects improving fundamental sentiment.
The principal obstacle is valuation and positioning. After a triple-digit run, the stock trades near or above several analysts' targets, and the wide $27-to-$49 range signals genuine disagreement about how much of the turnaround is already discounted. Oscar's heavy concentration in ACA individual plans leaves it exposed to federal subsidy and regulatory changes, a recurring risk for marketplace insurers. Medical cost trends could also pressure margins if claims accelerate. Insider activity adds a cautionary note: the CEO and other officers and directors have sold significant share volumes through 2026, which some investors read as a signal of limited near-term upside.
The stock reversed sharply after briefly touching $37.50–$37.95 in pre-market trading following its early-November earnings report, closing lower despite the beat. The $38.50 52-week high is the key overhead resistance zone, with the $40 level serving as the next psychological barrier. On the downside, the $30–$31 area, near recent consolidation, is a meaningful support level to watch, though it is far above the 52-week low. The share price has slipped back below shorter-term moving averages, indicating the rally is consolidating rather than extending in a straight line.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms rarely publish identical timeframes. Investors focused on the $37 target should watch quarterly medical cost ratios and membership growth, the next earnings report and any guidance updates, further analyst revisions (particularly from the bearish camp), and federal developments affecting ACA subsidies. Elevated insider selling and the stock's reaction around the $38.50 prior high are also worth monitoring for signs of whether the rally can resume.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. Traders use the tool to surface opportunities, track existing positions, and spot changing trends more efficiently than manual scanning allows. For those following names like OSCR alongside broader market moves, the signals offer a systematic way to stay ahead of momentum shifts.
The $37 target — the mean of nine verified analyst price targets — represents about 15% upside from the latest price, a level just below the stock's own 52-week high. Reaching it would require Oscar Health to keep converting rapid revenue growth into expanding margins while sidestepping ACA policy risk and valuation fatigue. The bullish case rests on raised guidance and a string of upgrades; the cautious case points to a stock trading near or above several targets, heavy insider selling, and a wide, divided analyst range. With targets clustered from $27 to $49, the balance of evidence suggests the target is reachable but far from assured, and investors should treat the figure as an analytical benchmark rather than a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, OSCR has been loosely correlated with CNC. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if OSCR jumps, then CNC could also see price increases.
| Ticker / NAME | Correlation To OSCR | 1D Price Change % | ||
|---|---|---|---|---|
| OSCR | 100% | +4.14% | ||
| CNC - OSCR | 54% Loosely correlated | +2.41% | ||
| ELV - OSCR | 41% Loosely correlated | +2.73% | ||
| UNH - OSCR | 37% Loosely correlated | +1.89% | ||
| CI - OSCR | 37% Loosely correlated | +2.55% | ||
| MOH - OSCR | 37% Loosely correlated | +1.48% | ||
More | ||||